EUCTR2009-014406-34-GB进行中（未招募）1 期
International, multicenter, randomized, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV patients with long-term viral suppression - ERAMUNE-01
ORVACS0 个研究点目标入组 28 人开始时间: 2010年3月17日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- HIV-1 infection, documented by any licensed ELISA test kit and confirmed by Western Blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test - 18 = Age = 70 years - At least 3 years of suppressive ART without any interruption (less than one month cumulative), - ART treatment unchanged in the 3 months prior to screening - One HIV plasma viral load (RNA) documented at least 3 years prior to entry, and at least 2 HIV plasma viral loads (RNA) documented per year thereafter - HIV plasma viral load (RNA) = 500 copies/ml at least 3 years prior to entry and HIV plasma viral load = 500 copies/ml for 90% of the measures thereafter - HIV plasma viral load (RNA) below the limit of detection for all values within the past year. Note: the assay used must have a lower limit of detection of 75 copies/ml or less - CD4+ count = 350 cells/mm3 within 60 days of entry - 10 = Proviral DNA = 1000 copies/106 PBMCs within 60 days of entry - Documented laboratory values: Haemoglobin = 10 g/dl, Platelets = 100,000 per microliter, Hepatic transaminases = 2.5 x ULN, Creatinine clearance = 50 ml/min by the Cockcroft –Gault equation - All subjects must agree not to participate in the conception process (e.g. active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, the subject/partner must use at least two reliable forms of contraceptives (condoms, with or without spermicidal agent, a diaphragm or cervical cap with spermicide, an IUD, or hormone-based contraception), while receiving study treatment and for 6 weeks after stopping study treatment - Ability and willingness to provide informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 28
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •- Sexually active men and women who will not practice at least one form of barrier birth control (male partner using condoms, female partner using condoms, other barrier contraception, etc) - Pregnancy as documented by a urine pregnancy test, or lactating women - Hepatitis B antigen (HBsAg) positive - Hepatitis C virus (HCV-Ab) positive or HCV RNA detectable - Previous use of an integrase inhibitor (ie raltegravir) or a CCR5 inhibitor (ie maraviroc, vicriviroc). Use of Raltegravir for non-treatment failure indications such as intensification and toxicity switches is allowed, provided that 1) virologic suppression was maintained before, during and after raltegravir treatment and 2) the patient has not received raltegravir treatment in the 6 months prior to the study entry. - Previous immunologic therapeutic intervention (e.g. IL-2, IL-7) within the past year - Participation in another clinical drug or device trial where the last dose of drug was within the past 30 days or an investigational medical device is currently implanted - Diagnosis of cancer within the last 5 years (except basal cell cutaneous cancers and cutaneous KS not requiring systemic therapy - Co-morbid condition with an expected survival less than 12 months - History of hypersensitivity to vaccination - History of autoimmune disease, such as systemic lupus erythematosis (SLE) or Hashimoto’s thyroiditis - Active drug or alcohol use or dependence that, in the opinion of the center investigator, would interfere with adherence to study requirements.
研究者
相似试验
进行中（未招募）
不适用
International, multicenter, randomized, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV-infected patients with long-term viral suppression/Estudio internacional, multicéntrico, aleatorizado, no comparativo y controlado de intensificación terapéutica más inmunomodulación en pacientes infectados por VIH con supresión vírica prolongadaInfeccion por VIH-1 / HIV InfectionMedDRA version: 9Level: LLTClassification code 10008922Term: Chronic infection with HIVEUCTR2009-014406-34-ESORVACS28
进行中（未招募）
不适用
International, multicenter, randomized, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV patients with long-term viral suppression - ERAMUNE-01EUCTR2009-014406-34-FRORVACS28
进行中（未招募）
1 期
International, multicenter, randomized, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E (3.0 mg) once a week and SR34006 (2.5 mg) once a week, documenting the safety and efficacy of both compounds during a 6-month treatment, and demonstrating the neutralizing effect of SSR29261 on the SSR126517E-induced anti-Xa activity. - EQUINOXEUCTR2005-005326-30-ESSanofi-Synthelabo Recherche700
进行中（未招募）
不适用
International, multicenter, randomized, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E (3.0 mg) once a week and SR34006 (2.5 mg) once a week, documenting the safety and efficacy of both compounds during a 6-month treatment, and demonstrating the neutralizing effect of SSR29261 on the SSR126517E-induced anti-Xa activity. - EQUINOXPatients with confirmed acute symptomatic DVT of the lower limbsMedDRA version: 8.1Level: PTClassification code 10051055EUCTR2005-005326-30-BEsanofi-aventis recherche & développement700
进行中（未招募）
不适用
International, multicenter, randomized, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E (3.0 mg) once a week and SR34006 (2.5 mg) once a week, documenting the safety and efficacy of both compounds during a 6-month treatment, and demonstrating the neutralizing effect of SSR29261 on the SSR126517E-induced anti-Xa activity. - EQUINOXEUCTR2005-005326-30-CZsanofi-aventis recherche & développement700